Readystate Asset Management LP Makes New $4.40 Million Investment in MiniMed Group Inc $MMED

Readystate Asset Management LP bought a new stake in MiniMed Group Inc (NASDAQ:MMED) in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 294,284 shares of the company’s stock, valued at approximately $4,400,000.

Other institutional investors and hedge funds also recently modified their holdings of the company. Legal & General Group Plc purchased a new position in MiniMed Group in the second quarter worth $91,000. The Manufacturers Life Insurance Company purchased a new stake in shares of MiniMed Group during the 2nd quarter valued at $185,000. Punch & Associates Investment Management Inc. purchased a new stake in shares of MiniMed Group during the 2nd quarter valued at $292,000. Washington Growth Strategies LLC bought a new stake in shares of MiniMed Group during the 2nd quarter worth $397,000. Finally, Deutsche Bank AG purchased a new position in shares of MiniMed Group in the 2nd quarter worth about $420,000.

MiniMed Group Stock Performance

NASDAQ:MMED opened at $23.28 on Monday. The company’s fifty day moving average is $18.21. The company has a market cap of $6.55 billion and a price-to-earnings ratio of -34.24. MiniMed Group Inc has a 52-week low of $10.65 and a 52-week high of $24.43.

Analysts Set New Price Targets

MMED has been the subject of a number of research analyst reports. Benchmark restated a “buy” rating on shares of MiniMed Group in a report on Thursday, June 4th. Morgan Stanley boosted their target price on shares of MiniMed Group from $19.00 to $21.00 and gave the company an “overweight” rating in a research note on Thursday. Bank of America increased their target price on shares of MiniMed Group from $24.00 to $28.00 and gave the company a “buy” rating in a research report on Wednesday, September 2nd. Weiss Ratings raised shares of MiniMed Group from a “sell (e+)” rating to a “sell (d-)” rating in a report on Monday, July 20th. Finally, BTIG Research upped their price objective on MiniMed Group from $25.00 to $28.00 and gave the company a “buy” rating in a research note on Tuesday, September 1st. Thirteen investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $23.77.

Trending Headlines about MiniMed Group

Here are the key news stories impacting MiniMed Group this week:

• Positive Sentiment: Analysts see further upside: Citigroup and Wells Fargo issued forecasts calling for strong price appreciation, while analysts at Mizuho, UBS Group, Bank of America and BTIG Research also said MiniMed’s share price is expected to rise. The cluster of bullish views may support investor confidence and buying interest. Citigroup forecast Wells Fargo forecast Mizuho analyst view UBS analyst view Bank of America analyst view BTIG analyst view
• Positive Sentiment: New products are driving optimism: A recent product introduction helped lift MiniMed’s top line, with further launches scheduled over the coming months. Investors appear to be viewing the product pipeline as a potential source of sustained growth. Why MiniMed stock was soaring
• Positive Sentiment: Operational momentum is improving: Coverage highlights recurring revenue streams, regulatory progress and a strong beginning to fiscal 2027, reinforcing the case for more predictable growth. Recurring revenues and product cycle Fiscal 2027 progress
• Neutral Sentiment: Morgan Stanley raised its target: The firm increased its target from $19 to $21 and maintained an “overweight” rating. However, the new target remains below the referenced recent trading level, suggesting that some expected gains may already be reflected in the valuation.

About MiniMed Group

We are a scaled global medical technology company that develops, manufactures, and markets a comprehensive suite of solutions for the management of diabetes. Since our founding more than 40 years ago, we have pioneered groundbreaking innovation and served the needs of our customers across the globe in service of our mission to make every day a better day for people with diabetes. Today, we are the only player in the market that commercializes all parts of an integrated diabetes management system.